A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor

Inclusion Criteria: 1. prescriptions explicitly given to the injection of Baijieyi; 2. confirmed by histopathological or cytological examination of malignant tumors and chemotherapy; 3. treatment: platelet count had reached below 75×10\^9/L after the treatment of chemotherapy and before using Baijieyi; prevention: patients with chemotherapy at the beginning of the preventive administration of BaiJieyi, and chemotherapy is same with previous cycle; 4. male or female, aged 18-85 years; 5. The main research information required is complete. Exclusion Criteria: 1. using other platelets of chemicals or biological products in the in the chemotherapy cycle used Baijieyi; 2. using drugs which can cause thrombocytopenia in the in the chemotherapy cycle used Baijieyi; 3. bone marrow dysfunction or bone marrow involvement; 4. There are other causes of thrombocytopenia, such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenic purpura, and hypersplenism, in the course of the use of Baijieyi.